Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Paracelsian Inc (PRLN) -- Ignore unavailable to you. Want to Upgrade?

To: John H. Farro who wrote (4197)	2/17/1999 9:59:00 PM
From: Jonathan Schonsheck	Read Replies (1) \| Respond to of 4342

My analysis of the Press Release. Well, the market has been underwhelmed by the recent press release. But for those of us who have been with the Company for a while, there is much of significance. The fact that Dr. Gurtoo is being named President of a Division gives us an insight into both the structure of the Company, and also the business plan. Adding personnel, and structuring, are both good signs. The business plan: "While the dietary supplement quality assurance and product development business built on BioFIT(tm) and the environmental monitoring business built on the Ah Immunoassay provide vehicles for reliable and steadily expanding revenue streams, drug development provides the opportunity for explosive appreciation in the Company's value," concluded Mr. Landes. Once upon a time, we were excited about the Company's moving forward with AndroVir and AndroCar. Now this: "Initially, we will make an effort to secure value added partnerships to accomplish three goals: 1) development of antiviral therapies based on the Company's Ah receptor patent and its Andrographolide patent, 2) screening of the Company's herbal extracts and the development of active extracts into potential therapeutic agents, and 3) evaluation of the Company's CDK assays as diagnostic and prognostic tools in cancer diagnosis and treatment," added Dr. Gurtoo. Those two "compounds" - protected by patents - are now but one-half of one of the three broad initiatives of one division of the Company. Mere profitability will arise from two of the others - BioFIT and Ah Immunoassay. We are looking to this division for "explosive appreciation in the Company's value." Finally, the tone of this press release is ratcheted up. While Bernie has always been "upbeat," this is different: "aggressive leadership," "explosive appreciation." And Gurtoo says: . "We believe that success in meeting these short-term goals will enable the Company to generate the capital necessary . . .." So those three initiatives are SHORT-term goals! It is hard to read these without believing that we will be reading more in the "short term." And remember: both the roll-out of BioFIT certified products, by Scherer, at EXPO west, with Danielle Lin, happens in March. And the results of testing at Southern Research Institute should be available in March too. Jonathan